Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatorygray marketresearch peptidesclinical practice

MDLinx warns clinicians about complications from DIY peptide injections

The clinician-facing piece frames self-sourced injectable peptides as an emerging presentation in outpatient practice.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 17 16:01 ETSource: MDLinx

The wire

  1. 01MDLinx published guidance for clinicians on patients arriving after self-administered peptide injections sourced outside the regulated supply chain.
  2. 02Clinicians and pharmacists fielding gray-market peptide use need a workup and counselling approach for unverified products and unknown doses.
  3. 03No article text accompanied the item, so the specific complications, evidence base and recommendations described cannot be detailed here.

From the source

When DIY peptide injections land patients in your clinic

Read at news.google.com